Bladder Cancer New Drug Sales Double... Nasdaq-Listed Bio Company Reduces Losses

UroGen Pharma Ltd. (NASDAQ: URGN) reported first-quarter 2026 revenues of $51.0 million—up 152% year-over-year and roughly KRW 70 billion. Sales of its lead bladder cancer therapy ZUSDURI more than doubled sequentially to $29.2 million, while its established product JELMYTO generated about $21.7 million, sustaining its growth trajectory. The company confirmed plans to file a U.S. New Drug Application for UGN-103, its urothelial cancer candidate, in the second half of 2026 and to submit an Investigational New Drug application for UGN-501 in Q2 2026. It also secured approximately $200 million in new financing to refinance existing debt and bolster working capital.

Alongside the earnings release, UroGen outlined a long-term growth scenario in which ZUSDURI could exceed $1 billion in annual sales and set full-year 2026 operating expense guidance at $240 million–$250 million. Its shares are trading near a 52-week high. In May, the company will participate in major U.S. healthcare investor conferences to update attendees on real-world prescription data and commercialization strategies for ZUSDURI and JELMYTO.

Headquartered in Israel and the United States, UroGen is a urologic oncology–focused biotech that employs its RTGel drug-delivery platform—which maintains viscosity in vivo—to develop non-invasive, localized treatments for bladder and upper urinary tract cancers. Given the high recurrence rates and substantial surgical burden in these indications, demand is growing for therapies that provide prolonged, local drug exposure, highlighting the market potential for these next-generation treatments.